24 RESULTS
Go to another page:
COMMENT I am a paid consultant for Biogen, so will not comment directly on the FDA’s deliberation of aducanumab. I raise here some general questions that may have an impact on AD therapeutics going forward as we are all taking stock of where we are with the data ...
COMMENT The COVID-19 pandemic has had a tremendous impact on human subjects research in which I am involved. Our overarching policy is that we need to minimize risk for study participants and research staff. We also are cognizant of resource utilization, e.g., ...
COMMENT These trial reanalyses look promising and have certainly rekindled enthusiasm for the amyloid hypothesis. I am a site investigator in one of these Biogen trials, hence will only comment in general terms because there may be efforts to re-enroll subjects. ...
COMMENT I have not seen the announcement, but my general comments relate to two questions: target and tools. For tau passive immunotherapy, the antibody would need to reach its target of a tau seed or a misfolded form of tau in sufficient amount to make a ...
COMMENT I read this paper with interest. There are many substrates besides VCAM1 that might be altered as a result of BACE-2 inhibition, with potentially unknown effects on the brain. The magnitude of alteration was clearly higher in the presence of TNF-α, which ...
COMMENT This plasma assay used IP-MS methodology, with standardization of plasma levels of Aβ42, 40, and a novel peptide by inclusion of Aβ38. The assay methods are well described, and the CV’s for the various plasma measures were low (around 5 percent). There ...
COMMENT The study of NfL in autosomal-dominant AD (ADAD) provides exciting preliminary evidence supporting this as a progression marker. The effect size was much more impressive in symptomatic patients than in preclinical carriers, and it will be interesting to ...
COMMENT Neurogranin appears to be an interesting and novel marker that appears to reflect post-synaptic damage. There are multiple proteolytically cleaved forms of neurogranin in CSF; this is reminiscent of tau, with which neurogranin correlates. It is possible ...
COMMENT Futility analysis has the potential to save unnecessary cost and participant exposure to a medication that does not work, and is a useful tool in clinical trials. For Alzheimer's disease, where the progression of pathology and clinical measures is ...
COMMENT The TEAM-AD study revives interest in two areas: treatment with antioxidants such as vitamin E, and carrying out clinical trials in patients with mild to moderate AD to evaluate effects on disease progression. The findings of a benefit in the vitamin E ...
COMMENT This study confirms the observation we made years ago that the majority of tau in cerebrospinal fluid (CSF) is not full-length, but consists of fragments that are detectable using N-terminal antibodies. This new study makes use of an extensive panel of ...
COMMENT Several of these awards focus on systems biology approaches, using human or animal model tissue, to identify networks and pathways implicated in Alzheimer's disease. Drs Bennett and De Jager have published several papers illustrating the opportunites ...
COMMENT This is an excellent and carefully conducted study, with implications for extrapolating from transgenic mouse models to human Alzheimer's disease. By characterizing two different transgenic models, one with less-aggressive amyloid pathology, the ...
COMMENT This is an interesting paper. It revisits aspects of standardization of Innogenetics Aβ assays (both ELISA and X-MAP) that have received attention before (e.g., by the Blennow and Shaw laboratories). Previous attempts have defined excellent within ...
COMMENT The editorial makes several important points. Perhaps the most important is that we need a much larger database to understand risks that transform TBI into CTE and its various clinical expressions among people at risk due to sports, war, or other ...
Go to another page:
